| No | Size | Price | Availability | |
| ARP8743-01 | 50ul | 1500.00 | In Stock |  |
| ARP8743-01 | 100ul | 2000.00 | In Stock | |
| Source: | Rabbit | Gene Id: | 8743 |
| Isotype: | IgG | Swiss Prot: | P50591 |
| purity: | Affinity purification |
| Background: |
| Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), also referred to as Apo2 ligand, first identified based on its sequence homology to TNF and Fas/Apo ligand is a member of the TNF family of cytokines and either exists as a type II membrane or soluble protein (1,2). TRAIL induces apoptosis in a variety of transformed cell lines and plays a role in anti-tumor and anti-viral immune surveillance (3). TRAIL signals via binding with death receptors DR4 (TRAIL-R1) (4) and DR5 (TRAIL-R2) (5-8) which can trigger apoptosis as well as NF-κB activation (7,9). Death domains on these receptors leads to the recruitment of a death-induced signaling complex (DISC) leading to caspase-8 and subsequent caspase-3 activation. In addition, TRAIL binds with decoy receptors DcR1 (TRAIL-R3) (10-13) and DcR2 (TRAIL-R4, TRUNDD) (14-15) which lack the functional cytoplasmic death domain antagonizing TRAIL-induced apoptosis. Osteoprotegerin (OPG) has also been identified as receptor capable of inhibiting TRAIL-induced apoptosis (16). The selectivity of soluble TRAIL at triggering apoptosis in transformed cells as compared to normal cells has led to its investigation as a potential cancer therapeutic (17-18). |
| Reactivity | Human |
| Tested applications | WB IHC |
| Clonality | Polyclonal Antibody |
| Calculated MW | 33 kDa |
| Recommended Dilutions |
WB 1:500-1:2000
IHC 1:50-1:200
|
| Immunogen | A synthetic peptide of human TNFSF10 |
| Storage | Store at -20°C or -80°C in PBS with 0.02% sodium azide and 50% glycerol. Avoid freeze/thaw cycles. |
| Synonym | APO2L, Apo-2L, CD253, TL2, TRAIL |
沪ICP备15003525号-1 Copyright ©, 2013-2022, Yihyson All Rights Reserved.
